lung cancer
JLAB_QUICKFIRE-2018-06-12

肺癌创新Quickfire挑战

挑战结束了

$ 750,000(470万日元)的赠款 +居住 +指导

手术肿瘤学
疗法

Awardees

肺%20CANCER%20innovation%20QFC%20Awardees.png

DNX生物制药

DNX Biois a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.

鹰眼简历

鹰眼简历启动于2018年在加州commercializ吗e novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.

NE科学

NE科学是一家位于波士顿的初创公司,开发了一种外科指导软件,用于在肝脏和肺部肿瘤经皮消融过程中支持医生靶向组织。Accublate(TM)指导软件在消融过程中实时模拟物理学,并以特定于患者的方式确定消融体积。该信息是在术中生成的,并覆盖为患者的CT图像,帮助医生完成所有恶性组织的完整治疗。

[1]HawkeyeBio.com, 2019

挑战

图像段落

普通人每天呼吸432升氧气,这是维持体内数万亿个细胞的重要组成部分。人类只能在没有氧气的情况下生存几分钟。为此,我们必须保护肺部至关重要。

在接触致癌物之后,有没有办法清洁肺部,就像牙刷在进食后清洁嘴吗?是否有一种方法可以像防晒霜那样将肺部免受致癌物的影响,使我们免受损坏的紫外线暴露?这些是约翰逊和约翰逊创新希望通过肺癌创新Quickfire挑战引发的一些挑衅性思想。

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year. Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth. Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.

Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health. How do we leverage the totality of science and technology to achieve comprehensive lung health - to ultimately prevent, intercept and cure lung cancer?

多达三个具有最佳想法,技术或解决方案的创新者,可以改善与预防,拦截或治愈肺癌相关的人类医疗保健a total of $750,000 in grants, a在JLABS @上海(可选)的居留凭证,包括实验室长凳,工作站和进入JLABS社区的访问以及Johnson&Johnson Innovation和/或其分支机构的指导。

Reward

Up to $750,000 (¥4,775,850) in total grants
  • JLABS @上海的1年居留权(可选)
  • Johnson&Johnson Innovation和/或其分支机构的专家的指导和指导

Areas of Interest

我们鼓励从事肺部各个方面的创新者的应用,包括针对肺癌的解决方案:

  • Prevention: Approaches to identify risks and for warding off onset of lung cancer
  • 拦截:在临床发作之前停止肺癌随着肺癌的发展
  • Cures:完全消除了肺癌的存在和逆转损害以恢复健康

请记住,不要太大或太早以供考虑。在评估期间,还将考虑清楚地描述实现这些目标的概念或前进的概念或途径的应用。

我们对解决肺部健康范围的应用程序感兴趣。特定感兴趣的领域包括但不限于:

  • To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation
  • 开发方法来测量呼吸致癌物的暴露和生物学作用
  • To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
  • 开发方法,包括手术,医学,行为,数字或其他方法,以防止或拦截肺癌发生
  • To discover new tools for diagnosis and extirpation of curable lung cancers
  • 开发新的治疗方法或治疗肺癌的治疗方式

Approaches should include the following areas:

  • 药品
  • 消费产品
  • 医疗设备
  • 全球公共卫生
  • 健康技术
  • 跨部门倡议 - 上述重点领域的一个或多个集成

申请流程

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • 潜在影响
  • Uniqueness of solution & level of competition in current market
  • 技术的质量和可行性
  • 团队信誉和能力
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

时间线

June 14, 2018 (China Time)
申请开放
September 21, 2018 (China Time)
提交截止日期
2019年春季
jlabs @上海发布会的获胜者公告

申请Now


不要错过截止日期

为什么这个挑战对我们很重要

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

常见问题解答

问:如果我在访问门户网站上遇到麻烦怎么办?

答:确保您的浏览器是最新的,并接受cookie。您可以通过[email protected]如果您也遇到技术困难。

问:jlabs @上海是否需要居住?

A: No. Residency is encouraged but optional.

问:我需要居住在上海还是中国实体才能申请?

答:不。我们正在全球寻求创新。

问:对于涉及JLAB居住的奖品,这需要什么以及有多少人?

答:对于涉及JLABS居住的挑战,该挑战需要1个实验室长凳和1个工作站(Desk),最多2人。如果您有更多的员工,可以租用更多的足迹。

问:对于涉及JLABS居留权的奖品,JLABS是否没有支出任何费用?

A: Each applicant will be required to submit to a background check, which is subject to a minimal fee. We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS. There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

问:JLABS会为我的生活费用,搬迁或签证付费吗?

A: No, any additional fees and paperwork are up to the winner.

问:我可以作为我的应用程序的一部分提交支持文档(例如视频)吗?

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

Q: Is it ok if some of the information I submit is confidential?

答:不要提交机密信息。仅应提交非固定信息,并且您提交的任何内容都将被视为非机密。

Q: What happens with IP (Intellectual Property)?

答:由于这是一个没有字符串的安排,因此JLABS不会获得任何IP。任何IP创建和/或保护仍然是发明者的唯一责任。

Q: Is a patent required to apply?

A: No, a patent is not required to apply. However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

问:哪种科学 /技术适合挑战?

A: We encourage all to apply. Find out more about what areas we desire to explore here:https://www.jnjinnovation.com/partnering

问:谁有资格申请?

答:每个挑战都有自己的条款和条件,可以在填写申请书之前找到。

问:应用的具体标准是什么?

A: Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • 潜在影响
  • Uniqueness of solution & level of competition in current market
  • 技术的质量和可行性
  • 团队信誉和能力
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

问:如果我对挑战或申请过程有疑问,我可以联系谁?

答:请联系[email protected]有任何疑问。

问:我在哪里申请?我必须一次坐下来完成申请吗?

答:申请https://www.2574design.com/form/lung-qfc-apply。您可以保存工作并登录,以便在需要时在以后的时间完成。

关于约翰逊和约翰逊创新,jlabs

图片1.png

Johnson&Johnson Innovation,JLABS(JLABS)是一个全球开放创新生态系统的网络,使和授权创新者能够为世界各地的患者创造和加速挽救生命,增强生命的健康和健康解决方案。JLABS通过为新兴公司提供最佳环境来实现这一点明天的突破性医疗解决方案。在JLABS,我们珍视伟大的想法,并热衷于消除成功的障碍,以帮助创新者释放其早期科学发现的潜力。JLABS是一个无弦的模型,这意味着企业家可以在坚持其知识产权的同时自由发展科学。JLABS向包括药品,医疗设备,消费者和数字健康部门在内的广泛医疗保健领域开放企业家。

JLABS目前在世界各地的创新热点地区都有地点,并制作了企业家计划和运动,以寻求最好的科学,例如全球的Quickfire挑战。乐动体育为什么赞助西甲JLABS旗舰店于2012年在圣地亚哥的Janssen西海岸研究中心开业,从那时起,在旧金​​山建立了两个地点 - 一个通过与加利福尼亚州定量生物科学研究所(QB3)合作,在South San san San San San San San San San San San San San San San Sandity建立了两个地点。弗朗西斯科。JLABS还通过与德克萨斯州医疗中心(TMC)的合作,通过与安大略省政府和多伦多大学的多伦多合作,通过与休斯敦的UMass合作,通过与UMASS合作在马萨诸塞州洛厄尔的Labcentral合作,位于波士顿。。纽约市和上海的新JLABS已宣布,2018年2月,总部位于比利时的Jlinx孵化器开始过渡到JLABS,这使其成为欧洲的第一批JLABS。有关JLABS的更多信息,请访问www.2574design.com

关于约翰逊和约翰逊(中国)投资有限公司

图片1_0.png

强生公司

强生是全球业务分布广泛、综合性的跨国医疗保健企业,业务涉及消费品、制药、医疗器材三大领域,1985年在华创立了第一家合资企业。强生遵循企业信条的价值观,致力于践行“关爱全世界,,,,关注每个人”的健康愿景,以领先的科技研发创造创新的理念、产品和服务,为改善人类健康和福祉而不懈努力。每天,强生遍布世界各地的员工,与他们的合作方一起,为全球消费者和病患带来更健康、更快乐、更长寿的生活。


Baidu